IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

Sep.20.2024
IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade
Canadian brand IGNITE drew attention at the Dortmund tobacco exhibition with its innovative products from September 19-21.

At the Dortmund Tobacco Expo from September 19 to 21, the Canadian brand IGNITE attracted a lot of attention with its innovative products. Lisa Kabatsky, Global Operations Manager of IGNITE International Brands, told 2Firsts that at this exhibition, IGNITE showcased two disposable products, v8000 and v15000. The v8000 was launched last year, while the v15000 was just released a few months ago and had not yet been introduced to the German market.

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

Lisa Kabatsky, Global Operations Manager of IGNITE International Brand, | Image source: 2Firsts

 

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

IGNITE has released disposable products v8000 and v15000. | Image source: 2Firsts.

 

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

IGNITEdisposable product v8000 | Image source: 2Firsts

 

Due to strict regulations in the local market, IGNITE is focusing on promoting low-nicotine products in the German market, while simultaneously developing switchable products that comply with regulations. Lisa Kabatsky stated that there is high demand for ice-flavored products in the German market, with no strong preference for other flavors and no noticeable trends.

 

IGNITE has expressed their views on the future trends of e-cigarettes to 2Firsts. Lisa Kabatsky believes that smart e-cigarettes are the way of the future, with the company upgrading their v15000 model and planning to equip it with a smart side screen to cater to the market's demand for smart products. Additionally, Lisa Kabatsky stated that IGNITE is also producing n-in-1 and 2+10 products, expected to be launched in the UK and EU regions, further expanding the company's market presence.

 

Lisa Kabatsky criticizes the regulatory policies issued by the United States FDA, stating that they have a negative impact on industry innovation and corporate development.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Company Limited announced its audited results for the year ended December 31, 2025. Revenue was HK$14.58 billion, profit before taxation was HK$1.28 billion, and profit attributable to owners of the Company was HK$0.98 billion, with basic and diluted EPS of HK$1.42. The Board proposed a final dividend of HK$0.33 per share; together with an interim dividend of HK$0.19 per share, the full-year dividend totaled HK$0.52 per share.
Mar.06 by 2FIRSTS.ai
Scandinavian Tobacco Group to Hold Annual General Meeting on April 15
Scandinavian Tobacco Group to Hold Annual General Meeting on April 15
Scandinavian Tobacco Group A/S has issued notice of its annual general meeting, which will be held on April 15, 2026 at 4:30 p.m. in Copenhagen and will also be available by live webcast.
Mar.25 by 2FIRSTS.ai
Poland to Discuss Revised E-Cigarette Definitions With Focus on Induction Technology
Poland to Discuss Revised E-Cigarette Definitions With Focus on Induction Technology
According to the agenda published by Poland’s Council of Ministers on Monday, the government is set to consider a draft amendment to the Excise Tax Act on Tuesday.
Apr.14 by 2FIRSTS.ai
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
The FDA updated public records on the PMTA authorization of a Glas vape product, renaming “Glas G Device” to “Glas G² Device” and releasing the order letter detailing scientific review and marketing restrictions. Company disclosures suggest the platform may include age-verification technology. If confirmed, Glas G² could be the first vape with device-level age verification to receive an FDA MGO. Glas executives also said menthol and other flavored pods could gain authorization in the future.
Special Report
Mar.14
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai